What's in Shanghai JMT-Bio Inc.'s pipeline?

Shanghai JMT-Bio Inc. has 13 drugs in our index: 0 marketed, 0 filed, 6 in Phase 3, 2 in Phase 2, 5 in Phase 1.

Which companies overlap with Shanghai JMT-Bio Inc.'s portfolio?

Top competitors by shared drug class: Qilu Pharmaceutical Co., Ltd., Hoffmann-La Roche, Pfizer, Sanofi, AstraZeneca.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/shanghai-jmt-bio-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Shanghai JMT-Bio Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shanghai JMT-Bio Inc. pipeline: 0 marketed, 0 filed, 6 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 6 Phase 3 2 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
JMT101 injection	JMT101 injection	phase 3	monoclonal antibody	unknown	Immunology
JMT103	JMT103	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
HB1801	HB1801	phase 3	Bispecific antibody		Oncology
SG001	SG001	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
KN026	KN026	phase 3	Bispecific monoclonal antibody	HER2 and HER3	Oncology
Osimertinib tablet	Osimertinib tablet	phase 3	EGFR tyrosine kinase inhibitor (third-generation)	EGFR (Epidermal Growth Factor Receptor)	Oncology

Therapeutic area mix

Oncology · 3
Diabetes · 2
Immunology · 2
Osteoporosis · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Qilu Pharmaceutical Co., Ltd. · 4 shared drug classes
Hoffmann-La Roche · 4 shared drug classes
Pfizer · 4 shared drug classes
Sanofi · 3 shared drug classes
AstraZeneca · 3 shared drug classes
Novartis · 3 shared drug classes
Allergan · 3 shared drug classes
Avalo Therapeutics, Inc. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Shanghai JMT-Bio Inc.:

Cite this brief

Drug Landscape (2026). Shanghai JMT-Bio Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-jmt-bio-inc. Accessed 2026-05-16.